"text","label","instanceType","uuid:ID","id","description","name"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective","7ce68c9d-6504-4c93-bac0-92e2e5eac767","Objective_1","Main objective","OBJ1"
"To document the safety profile of the xanomeline TTS.","","Objective","b1032387-4b4c-440d-9f82-9649a9d66fca","Objective_2","Safety","OBJ2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective","2b628982-8a54-4621-927f-c29064a3dd91","Objective_3","Behaviour","OBJ3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective","5eb42c47-1537-49ba-8b4c-e955d6c0ebe8","Objective_4","","OBJ4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective","56a8477e-3e78-4767-903d-93dc4040c200","Objective_5","","OBJ5"
"To assess the treatment response as a function of Apo E genotype.","","Objective","92fd688c-bd5b-427f-a34d-e206ff635bf5","Objective_6","","OBJ6"
